About catalyst pharmaceuticals inc - CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
CPRX At a Glance
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Coral Gables, Florida 33134
| Phone | 1-305-420-3200 | Revenue | 588.99M | |
| Industry | Pharmaceuticals: Major | Net Income | 214.33M | |
| Sector | Health Technology | 2025 Sales Growth | 19.778% | |
| Fiscal Year-end | 12 / 2026 | Employees | 182 | |
| View SEC Filings |
CPRX Valuation
| P/E Current | 14.66 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.858 |
| Price to Sales Ratio | 5.043 |
| Price to Book Ratio | 2.997 |
| Price to Cash Flow Ratio | 14.23 |
| Enterprise Value to EBITDA | 7.649 |
| Enterprise Value to Sales | 3.844 |
| Total Debt to Enterprise Value | 0.001 |
CPRX Efficiency
| Revenue/Employee | 3,236,203.297 |
| Income Per Employee | 1,177,615.385 |
| Receivables Turnover | 4.592 |
| Total Asset Turnover | 0.601 |
CPRX Liquidity
| Current Ratio | 6.076 |
| Quick Ratio | 5.823 |
| Cash Ratio | 4.819 |
CPRX Profitability
| Gross Margin | 78.819 |
| Operating Margin | 43.766 |
| Pretax Margin | 48.136 |
| Net Margin | 36.389 |
| Return on Assets | 21.856 |
| Return on Equity | 25.486 |
| Return on Total Capital | 22.394 |
| Return on Invested Capital | 25.409 |
CPRX Capital Structure
| Total Debt to Total Equity | 0.292 |
| Total Debt to Total Capital | 0.291 |
| Total Debt to Total Assets | 0.252 |
| Long-Term Debt to Equity | 0.246 |
| Long-Term Debt to Total Capital | 0.246 |